Calcijex is a brand name of calcitriol, approved by the FDA in the following formulation(s):
CALCIJEX (calcitriol - injectable; injection)
Manufacturer: ABBOTT
Approval date: September 25, 1986
Strength(s): 0.001MG/ML [RLD][AP], 0.002MG/ML [RLD][AP]
Has a generic version of Calcijex been approved?
A generic version of Calcijex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Calcijex and have been approved by the FDA:
calcitriol injectable; injection
Manufacturer: AKORN
Approval date: January 29, 2008
Strength(s): 0.001MG/ML [AP], 0.002MG/ML [AP]
Manufacturer: APP PHARMS
Approval date: December 31, 2002
Strength(s): 0.001MG/ML [AP], 0.002MG/ML [AP]
Manufacturer: FRESENIUS MEDCL
Approval date: February 20, 2003
Strength(s): 0.001MG/ML [AP], 0.002MG/ML [AP]
Manufacturer: LUITPOLD
Approval date: September 26, 2003
Strength(s): 0.001MG/ML [AP], 0.002MG/ML [AP]
Manufacturer: ROCKWELL MEDCL
Approval date: September 17, 2003
Strength(s): 0.001MG/ML [AP]
Manufacturer: SAGENT PHARMS
Approval date: February 8, 2006
Strength(s): 0.001MG/ML [AP]
Manufacturer: TEVA PARENTERAL
Approval date: March 31, 2003
Strength(s): 0.002MG/ML [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Calcijex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Low oxygen content compositions of 1.alpha., 25-dihydroxycholecalciferol
Patent 6,051,567
Issued: April 18, 2000
Inventor(s): Abrahamson; Kent & Anderson; Amy N. & Grady; Haiyan
Assignee(s): Abbott Laboratories
The invention relates to stable aqueous formulations comprising 1.alpha., 25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.Patent expiration dates:
- August 2, 2019
- February 2, 2020✓
- August 2, 2019
Low oxygen content compositions of 1.alpha., 25-dihydroxycholeclciferol
Patent 6,265,392
Issued: July 24, 2001
Inventor(s): Abrahamson; Kent & Anderson; Amy N. & Grady; Haiyan
Assignee(s): Abbott Laboratories
The invention relates to stable aqueous formulations comprising 1.alpha.,25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.Patent expiration dates:
- August 2, 2019
- February 2, 2020✓
- August 2, 2019
Low oxygen content compostions of 1.alpha., 25-dihydroxycholecalciferol
Patent 6,274,169
Issued: August 14, 2001
Inventor(s): Abrahamson; Kent & Anderson; Amy N. & Grady; Haiyan & Hartmann; Kurt J. & Farmer; Randall M. & Oberdier; John P.
Assignee(s): Abbott Laboratories
The invention relates to stable compositions comprising 1.alpha., 25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.Patent expiration dates:
- August 2, 2019
- February 2, 2020✓
- August 2, 2019
See also...
- Calcijex Solution Consumer Information (Wolters Kluwer)
- Calcitriol Consumer Information (Wolters Kluwer)
- Calcitriol Solution Consumer Information (Wolters Kluwer)
- Calcitriol Consumer Information (Cerner Multum)
- Calcitriol AHFS DI Monographs (ASHP)
No comments:
Post a Comment